Female Stress Urinary Incontinence
Treatment depends on symptom burden, urethral support and function, prior surgery, emptying, health and patient goals. Discuss observation, pelvic-floor muscle training, continence devices and procedural options. AUA/SUFU permits continence pessaries and vaginal inserts ; NICE limits intravaginal and intraurethral devices to occasional use, and EAU 2026 recommends against mechanical devices for mild-to-moderate SUI outside closely monitored research .[1][2][4]
Assessment and Treatment Selection
Before an operation, document leakage with a standardized cough stress test at an adequately filled bladder, pelvic examination, urinalysis and postvoid residual.[4] Urethral mobility and sphincter function are separate assessments. Urodynamics may be omitted in an uncomplicated index patient with clearly demonstrated SUI; uncertainty, voiding dysfunction, prior surgery or other non-index features warrant additional evaluation.[1][2]
| Clinical situation | Options to discuss | Important distinction |
|---|---|---|
| Primary SUI or stress-predominant mixed incontinence | PFMT, continence pessary; MUS, autologous PVS, Burch or bulking when a procedure is chosen | Expected stress-leakage benefit and urgency outcomes differ. Treatment is a shared choice. |
| Mesh avoidance | Autologous PVS, Burch, or bulking | PVS adds harvest morbidity; Burch requires abdominal access; bulking may need repeat treatment. |
| Lower procedural burden preferred | Continence devices or urethral bulking | Anesthesia and repeat-treatment needs depend on the procedure and setting. |
| Fixed, immobile urethra | PVS, retropubic MUS, bulking or an adjustable retropubic sling | AUA/SUFU's discussion favors PVS for a nonmobile urethra. |
| Concurrent urethral diverticulectomy, urethrovaginal fistula repair or urethral mesh excision | Individualize concurrent versus staged continence surgery; autologous fascia if an accompanying sling is appropriate | Avoid a synthetic MUS during these repairs. Remote healed surgery is a different situation. |
| Prolapse with symptomatic, occult or absent SUI | Concomitant versus staged continence treatment | Separate these populations and the prolapse route. EAU 2026 recommends against concomitant anti-incontinence surgery during abdominal prolapse repair in women without symptomatic or occult SUI ; for symptomatic or occult SUI, it recommends discussing combined-surgery risks and benefits .[4] |
| Recurrent SUI after surgery | Reassess stress leakage, urgency, obstruction, emptying, tissue and prior implants before choosing further treatment | — |
| Severe refractory outlet dysfunction | Specialist discussion of reconstructive options, selected obstructing PVS or bladder-neck closure with drainage; selected female AUS after failed surgery | Bladder storage safety, catheterization ability, device revisions and irreversible consequences require explicit planning. |
| Genitourinary syndrome of menopause | Treat coexisting GSM, including vaginal estrogen when appropriate | EAU 2026 recommends vaginal estrogen for postmenopausal SUI with vulvovaginal atrophy , based on short-term symptom improvement; NICE offers it when OAB symptoms coexist with menopausal genitourinary symptoms and signs. Assess demonstrable SUI and discuss other indicated treatments.[1][2][4] |
The framework reflects AUA/SUFU and NICE guidance. EAU 2026 recommends informing women offered a single-incision sling that long-term efficacy remains uncertain .[4] Recommendations differ by jurisdiction: AUA/SUFU permits retropubic, transobturator and single-incision MUS in index patients, whereas NICE offers colposuspension or an autologous rectus fascial sling (with a retropubic mesh sling included in the choice), reserves the transobturator route for circumstances in which the retropubic approach should be avoided, limits single-incision short mesh slings to clinical trials, and offers an artificial urinary sphincter only after previous surgery has failed.[1][2] NICE also advises against anterior colporrhaphy, needle suspension, paravaginal defect repair, porcine dermis slings and the Marshall-Marchetti-Krantz procedure for SUI.[1][2] The needle suspensions and in situ vaginal wall slings that women may report from earlier decades are described on the historical needle suspension page.
The EAU 2026 guideline recommends (Strong unless stated) supervised pelvic floor training of at least three months first-line for SUI and MUI, then offers a choice of colposuspension, autologous sling, urethral bulking or midurethral sling after shared decision-making. It advises cystoscopy when placing a synthetic MUS, telling women that long-term outcomes are better with the retropubic than the transobturator route, restricting adjustable midurethral slings for primary SUI surgery to well-regulated, closely monitored research studies , and using new SUI devices only in structured research with outcomes monitored in a registry or well-regulated study , and not offering autologous fat or hyaluronic acid as bulking agents. For complicated or recurrent SUI, EAU considers a secondary sling, bulking, Burch, autologous sling or AUS in experienced centers, warns that repeat surgery is generally less effective and riskier, and that AUS or ACT carries a high risk of complications, mechanical failure or explantation. Routine urodynamics are not advised for uncomplicated SUI but are advised with coexisting storage symptoms, unclear incontinence type, suspected voiding dysfunction, prolapse or prior SUI surgery.[4]
Three device-specific series provide historical context for the EAU 2026 research restriction on adjustable midurethral slings used for primary SUI, its experienced-center requirement for complicated SUI, and its warning about ACT harms (all Strong).[4] In a prospective REMEEX re-adjustable retropubic sling series for recurrent SUI or intrinsic sphincteric deficiency, 230 women underwent surgery, 25 were lost to follow-up, and 205 were evaluated; at a mean 89-month follow-up, 165 were cured of SUI (165/230 [71.7%] by intention-to-treat; 165/205 [80.5%] per protocol), with an overall complication rate of 28.8% (3.4% Clavien III); the series was uncontrolled and predates the current research-only restriction.[5] A separate readjustable system, the SAFYRE silicone-tail sling, has a transobturator crossover variant (SAFYRE T) described as a salvage option for severe SUI with a nonfunctional urethra after multiple failed procedures: each arm is passed transobturator and crossed behind the urethra for circumferential coaptation, with the tension adjustable after placement. In the initial 16-woman salvage series (all had at least two prior anti-incontinence procedures), mean 12-month follow-up showed 93.7% symptom cure, one intraoperative urethral perforation repaired primarily, and de novo urge incontinence in 2 women; the series was uncontrolled and reported by the technique's originating authors, and EAU 2026 recommends management of complicated SUI only in centers with appropriate experience ; its research-only restriction addresses adjustable midurethral slings used for primary SUI surgery .[4][7] For ACT/proACT peri-urethral balloons, a single-center survival analysis of 82 balloons (41 effective in 36 patients, both sexes) found that among patients who initially became continent, the probability of a further operation for loss of efficacy reached 50% by five years; prior radiotherapy, diabetes and a prior balloon placement significantly shortened failure-free survival.[6]
Comparing Operations
Use the dedicated retropubic MUS, transobturator MUS, single-incision sling, PVS, Burch and bulking pages for their trial populations, endpoints and harms. Discuss bladder injury, emptying, pain, mesh or suture complications, donor wounds, recovery and retreatment in the context of the actual operation.[1][2]
Cure, improvement and satisfaction are different outcomes. At five years in a randomized trial comparing tension-free vaginal tape with polyacrylamide hydrogel injection, satisfaction of at least 80/100 was reported by 89/96 (92.7%) versus 74/99 (74.7%); hydrogel did not meet the trial's noninferiority criterion for satisfaction, while perioperative or postoperative complications before crossover occurred in 42/96 (43.8%) versus 22/99 (22.2%).[8] Traditional-sling reviews also contain historical materials and techniques.[3]
Treatment Database
| Treatment | Category | Best for / indication |
|---|---|---|
| Pelvic Floor Physical Therapy (PFMT ± Biofeedback) | Conservative | Conservative treatment for SUI; supervised training and shared treatment goals. |
| Behavioral & Lifestyle Modifications | Conservative | Individualized fluid and caffeine advice; address constipation and smoking when relevant. |
| Weight Loss | Conservative | Weight management when appropriate; symptom benefit varies. |
| Continence Pessary | Conservative | Bridge to surgery, pregnancy plans, or non-surgical preference. |
| Poise Impressa | Conservative | Discontinued; formerly an OTC self-fitted intravaginal continence device for situational/activity-related SUI. See linked page for historical evidence. |
| Absorbent Products & Pad Test | Containment / Diagnostic | Containment during workup or treatment; pad-weight test for severity and outcome tracking. |
| Barrier Creams & IAD Prevention | Containment / Diagnostic | Chronic pad / catheter users; prevention and treatment of incontinence-associated dermatitis. |
| Pelvic Floor Electrical Stimulation | Conservative | Patients who cannot voluntarily contract the pelvic floor. |
| Duloxetine | Pharmacological | Selected SUI unresponsive to other conservative care when invasive treatment is declined and use is licensed <Rec>(EAU Weak)</Rec>; counsel on adverse effects and titrate initiation and withdrawal <Rec>(EAU Strong)</Rec>. NICE excludes first-line and routine second-line use (EAU 2026, ref. 4; NICE NG123, ref. 2). |
| Topical Vaginal Estrogen | Pharmacological | Postmenopausal SUI with GSM-driven irritative overlay. |
| Urethral Bulking Agents | Minimally Invasive | Lower procedural burden or preference against other surgery; discuss durability and repeat injections. |
| Vaginal Laser Therapy (CO₂ / Er:YAG) | Minimally Invasive | Investigational; FDA 2018 warning — research protocols only. |
| Retropubic Mid-Urethral Sling (TVT) | Surgical | Established SUI operation; counsel about retropubic passage and mesh risks. |
| Transobturator Mid-Urethral Sling (TOT / TVT-O) | Surgical | Selected SUI when retropubic access should be avoided; NICE restricts this route to specific circumstances (NICE NG123, ref. 2). Discuss groin pain and other route-specific risks. |
| Single-Incision Mini-Sling | Surgical | AUA/SUFU option for selected index SUI; NICE limits single-incision short mesh slings to clinical trials. EAU 2026 recommends counseling that long-term efficacy remains uncertain <Rec>(Strong)</Rec>.(AUA/SUFU 2023, ref. 1; NICE NG123, ref. 2; EAU 2026, ref. 4). |
| Autologous Fascial Pubovaginal Sling | Surgical | Primary or selected recurrent SUI; mesh avoidance or appropriate concurrent urethral repair. |
| Burch Colposuspension | Surgical | Mesh-free suture option when anatomy, abdominal access and patient goals are suitable. |
| Artificial Urinary Sphincter (AUS) | Salvage | Selected refractory SUI after failed surgery; specialist assessment and device counseling. |
| Obstructing Autologous PVS / Bladder-Neck Closure | Salvage | Selected severe outlet dysfunction; individualized safe storage and long-term urinary drainage. |
| Urinary Diversion | Salvage | Last resort — intractable incontinence with non-functional outlet. |
Videos
References
1. AUA/SUFU. Surgical Treatment of Female Stress Urinary Incontinence. 2023 amendment. Official guideline.
2. NICE. Urinary incontinence and pelvic organ prolapse in women: management. NG123. Recommendations.
3. Saraswat L, Rehman H, Omar MI, Cody JD, Aluko P, Glazener CMA. Traditional suburethral sling operations for urinary incontinence in women. Cochrane Database Syst Rev. 2020;1:CD001754. doi:10.1002/14651858.CD001754.pub5.
4. European Association of Urology. EAU Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms (LUTS) (Limited Update March 2026). Guideline.
5. Errando-Smet C, Ruiz CG, Bertrán PA, Mavrich HV. "A Re-Adjustable Sling for Female Recurrent Stress Incontinence and Intrinsic Sphincteric Deficiency: Long-Term Results in 205 Patients Using the Remeex Sling System." Neurourol Urodyn. 2018;37(4):1349-1355. doi:10.1002/nau.23444
6. Bajeot AS, Brierre T, Beauval JB, et al. "Survival Analysis of Adjustable Continence Therapy Device (ACT®/proACT®): A New Message for Patients." Prog Urol. 2021;31(4):215-222. doi:10.1016/j.purol.2020.10.005
7. Palma P, Riccetto C, Herrmann V, et al. "Transobturator Crossover Readjustable Sling for Severe Female Incontinence: Technique and Preliminary Results." Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(11):1277-1282. doi:10.1007/s00192-007-0320-1
8. Itkonen Freitas AM, Isaksson C, Rahkola-Soisalo P, Mentula M, Mikkola TS. "Tension-Free Vaginal Tape versus Polyacrylamide Hydrogel Injection for Stress Urinary Incontinence - 5-Year Follow-Up." NEJM Evid. 2025;4(5):EVIDoa2400216. doi:10.1056/EVIDoa2400216.